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Coexisting NPY and NE synergistically regulate renal tubular Na,
K-ATPase activity. The sympathetic renal nerves are of central impor-
tance for the regulation of sodium balance. Sodium excretion decreases
following renal nerve activation and increases following denervation.
These effects have been attributed to norepinephrine (NE) acting on
a-adrenergic receptors. In the present study, using isolated permeabi-
lized rat renal proximal convoluted tubule (PCT) cells, neuropeptide Y
(NPY) was shown to stimulate Na, K-ATPase activity. This 36-
amino acid peptide is a messenger molecule in the sympathetic nervous
system which is co-stored with NE and dopamine-/3-hydroxylase
(DBH), the NE synthesizing enzyme in the renal nerves. The effect is
likely to be mediated via the NPY Y2 receptor, a pertussis toxin
(PTX)-sensitive G-protein, and calcium. It is partically antagonized by
a-adrenergic antagonists, and enhanced by the subthreshold doses of
a-adrenergic agonists. Our results suggest an important role for this
peptide in the regulation of the sodium balance in the kidney.
Regulation of sodium excretion by renal sympathetic nerve
activity plays an important role for the maintenance of Na
homeostasis. Neuropeptide Y (NPY), a 36-amino acid peptide
structurally related to the pancreatic polypeptide family [1, 2],
is widely distributed throughout the nervous system, and often
co-localizes with norepinephrine (NE) in sympathetic nerves
[3]. Although immunocytochemical and radioimmunoassay
analyses have revealed the presence of NPY in renal vascular,
cortical, and corticomedullary tissue in the kidney [4, 5], the
role of NPY in the regulation of renal function is not fully
understood. Subpressor doses of NPY decrease renal blood
flow and glomerular filtration rate and these effects have been
associated with antinatriuresis [6, 7]. Whether the antinatriure-
sis is secondary to the changes in hemodynamics or whether
NPY might have a direct tubular effect has so far not been
examined.
a-Adrenergic receptor agonists will in many tissues act
synergistically with NPY [8, 9]. Activation of a-adrenergic
receptors stimulates proximal convoluted tubular (PCT) Nat,
KtATPase activity. This effect is mediated by the calcium
dependent protein phosphatase 2B (PP2B), calcineurin [10].
Here we report that NPY also stimulates rat PCT Na, K-
ATPase activity and in this respect acts synergistically with the
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a-adrenergic agonist, oxymetazoline, and that the signaling
pathway used by NPY is similar to that used by a-adrenergic
agonists in the proximal tubular cells.
Methods
Animals
Male Sprague-Dawley rats (ALAB, Sollentuna, Sweden), 40
to 45 days of age and weighing between 150 and 200 g, were
used in the experiments. The rats were fed ad libitum with
synthetic rat chow (R3, Ewos, Södertälje, Sweden) and free
access to tap water.
Immunohistochemistry of the renal tissue
The rats were anesthetized with sodium pentobarbital (Me-
bunal; 40 mglkg body wt i.p.) and preperfused with 50 ml of
warm (37°C) Tyrode's Ca2-free buffer and 50 ml of warm
(37°C) paraformaldehyde/picric acid mixture (4% paraformalde-
hyde and 0.4 % picric acid in 0.16 M sodium phosphate buffer,
pH 6.9) [11], followed by ice-cold fixative (as above). The
kidneys were rapidly dissected out and immersed in the same
fixative for 90 minutes, and then transferred to a 10% sucrose
solution containing 0.0 1% sodium azide (Merck, Darmstadt,
Germany) and 0.02% Bacitracin (Sigma Chemical Co., St.
Louis, Missouri., USA) in 0.1 M phosphate buffer (pH 7.4).
Sectioning was performed in a cryostat (Dittes, Heidelberg,
Germany) at a working temperature of —20°C and 14 xm
section thickness. The sections were processed according to the
indirect immunofluorescence technique [12]. Cryostat sections
were mounted on chrome alun-gelatin precoated glass slides
and incubated at 4°C in a humid chamber for 18 to 24 hours with
rabbit antiserum to NPY [13] or goat antiserum to dopamine-
/3-hydroxylase (DBH) antiserum [14] diluted 1:400 or 1:800,
respectively, in phosphate-buffered saline (PBS) (pH 7.4) con-
taining 0.3% Triton X-100. DBH is the enzyme converting
dopamine to NE, and is a marker for noradrenergic neurons.
The sections were incubated overnight at 4°C in a mixture of
primary rabbit antiserum to NPY or goat antiserum to DBH,
rinsed in PBS and incubated at 37°C for 30 minutes in a mixture
of fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit
(diluted 1:40; Boehringer Mannheim Scandinavia, Stockholm,
Sweden) or donkey anti-goat (diluted 1:10; Nordic Immunolog-
ical Laboratories, Tilburg, The Netherlands) secondary anti-
bodies, and thereafter rinsed again in PBS. In addition, sections
were incubated separately with each of the two antisera. NPY
antiserum preabsorbed with NPY peptide at 106 M (Peninsula
1606
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Labs., Inc., Belmont, California, USA) and normal goat serum
(for DBH) were used for control purposes. The sections were
finally mounted in a mixture of PBS and glycerol (1:3) contain-
ing 0.1% p-pheneylenediamine [15]. Microscopy was carried
out using a Nikon Microphot-FX epifluorescence microscope
equipped with filter cube B-2A for FITC-fluorescence (450 to
490 nm excitation filter and 520 nm barrier filter with an extra
520 to 550 nm barrier filter) and filter cube G- lB for TRITC-
fluorescence (546/10 nm excitation filter and 610 nm barrier
filter). Kodak Tri-X (Kodak, Rochester, New York, USA)
black and white film was used for photography.
Preparation of PCT
The rats were anesthetized with thiobutabarbital (mactin;
Byk-Gulden, Coblenz, Germany; 50 mg/kg body wt i.p.), ex-
cept those with left renal arteries denervated, and kidney
perfusion and tubule dissection were performed as described
[16]. Briefly, following a midline incision, the left kidney was
exposed and perfused with the modified Hanks' solution (in
mM):137 NaCI, 5 KC1, 0.8 MgSO4, 0.33 Na2HPO4, 0.44
KH2PO4, 0.25 CaCl2, 1 MgCl2, and 10 Tris-HC1, to which 0.05%
collagenase (Sigma) and bovine serum albumin (BSA) (Behring-
werke, Marburg, Germany) 0.1% were added; the pH was
adjusted to 7.4. The kidney was removed and cut along its
corticopapillary axis into small pyramids that were incubated
for 20 minutes at 35°C in the perfusion solution with iO— M
butyrate, bubbled with oxygen. To remove the collagenase, the
tissue was rinsed three times with the same solution as used for
perfusion, except that collagenase and BSA were omitted and
that the CaCl2 concentration was 0.25 mM (microdissection
solution). Butyrate (l0— M) was also added to this solution to
optimize the mitochondrial respiration [17].
Under stereomicroscopic guidance single PCT segments
were dissected (tubular length 0.5 to 1.0 mm) from the outer
cortex on ice, and individually transferred to the concavity of a
bacteriological slide in a drop of microdissection solution and
photographed in an inverted microscope at x 100 magnification
for length determination. They were stored on ice until dissec-
tion was completed (— 60 mm).
Incubation of tubules with peptides and/or drugs
Tubules were incubated for 30 minutes (for the time-course
studies, incubation periods were 5, 10, 15, or 20 mm) at room
temperature either in 1 l of microdissection solution alone
(control tubules) or in 1 .d of microdissection solution contain-
ing one or more of the drugs mentioned below (experimental
tubules); in most protocols the Na concentration was reduced
to 20 m, whereas in some protocols we varied the Na
concentration (from 3 to 70 mM). In one study, incubation was
carried out at 37°C for 5 or 10 minutes. When the Na
concentration was less than 70 mts, osmolality was kept con-
stant at 290 mOsmlkg of H20 by the addition of choline
chloride.
In one experiment, before incubating with NPY, tubules were
preincubated with or without 1 j.g/ml pertussis toxin (PTX) at
37°C for four hours under 95% 02 and 5% CO2 with a moist
atmosphere [18].
Test substances were added to the modified physiological
buffer. Porcine NPY, prazosin, yohimbine, and PTX were
purchased from Sigma Chemical Co.; [Leu31, Pro4] NPY and
NPY13_36 were gifts from Prof. J.M. Lundberg (Dept. of Phar-
macology, Karolinska Institutet, Sweden); FK 506 was ob-
tained from Jay Luly of Abbott Laboratories.
Determination of Na, K-ATPase activity
The preincubation period was stopped by placing the seg-
ments at 4°C, and the segments were made permeable by
hypotonic shock, freezing and thawing. Then they were imme-
diately incubated at 37°C for 15 minutes in a medium containing
(in mM): 20 NaC1 (except for one experiment as stated above),
5 KC1, 10 MgCl2, 1 EGTA, 100 Tris-HCI, 10 Tris-ATP, and
[y-32P] ATP (New England Nuclear, Boston, Massachusetts,
USA); 2 to S Ci mmol in tracer amounts (5 nCid1) in the
absence or presence of 2 mri ouabain (USB Corp., Cleveland,
Ohio, USA). For determination of ouabain-insensitive (Mg-
dependent) ATPase activity NaCl and KCI were omitted and
Tris-HCI was 150 m. The phosphate liberated by hydrolysis of
[y-32P] ATP was separated by filtration through a Millipore filter
after absorption of the unhydrolyzed nucleotide on activated
charcoal.
Total ATPase activity was measured on each of five to eight
tubule segments, and ouabain-sensitive ATPase activity was
measured on each of five to eight other tubule segments in a
liquid scintillation spectrophotometer. The difference between
the mean value for total ATPase and Mg-ATPase was used for
further calculations. In each assay we also determined 32P
released from [y.32P] ATP in four to six samples of incubation
solutions containing no tubular segments. The mean value of
these determination (blanks) was subtracted from each value
for 32P released from tubule incubations.
The enzyme activity is calculated as pmol of 32P1 hydrolyzed
per mm of tubule per hour, and is expressed either as absolute
values and percent values of those from control tubules.
Denervation of the left renal arteries
In one of the studies, the rats were unilaterally denervated.
Under light ether anesthesia, the left renal artery was dissected
free from surrounding tissue and wrapped three times for five
minutes with cotton soaked in a solution of 10% phenol in
absolute alcohol [19]. In those rats, the determination of Na,
K-ATPase activity was performed five to seven days later.
Statistical analysis
Values are given as mean SEM. Statistical analysis was
performed with the Student's t-test and analysis of variance. A
value of P <0.05 was considered significant.
Results
Immunohistochemical analysis
Numerous NPY- and DBH-positive nerve fibers were ob-
served, mainly around blood vessels, and with a strongly
overlapping distribution. In fact, the double-labeling experi-
ments showed an almost total coexistence of the two markers
(Figs. 1 and 2). In several cases, single nerve fiber containing
both NPY- and DBH-like immunoreactivities could be ob-
served close to proximal tubules. None of the above-described
fluorescent structures was seen after incubation with control
sera.
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Fig. 1. Immunofluorescence photomicrographs of sections of the rat kidney after double-staining with rabbit antiserum to neuropeptide Y (NPY)
(a, c) and goat antiserum to dopamine-13-hydroxylase (DBH) (b, d). Rectangles in a and b indicate higher magnifications as shown in c and d.
Comparison of a and c with b and d shows that nerve fibers located in the close vicinity of tubules exhibit both immunoreactivities. Small arrows
point to fiber varicosities exhibiting both NPY- and DBH-immunoreactivity. Large arrows point to fibers containing both NPY- and
DBH-immunoreactivity in close apposition to tubules. Abbreviations are: gI, glomeruli; tu, tubules. Bars = 100 jim.
-S.
Fig. 2. Immunofluorescence photomicrographs of sections of the rat
kidney after incubation with rabbit antiserum to NPY (a, c) and goat
antiserum to DBH (b). Double-staining with NPY (a) and DBH (b)
antisera shows several varicosities (arrows) in close apposition to
tubules (tu) that contain both immunoreactivities. Note also NPY
single-labeled fiber running close to a tubule. Bars = 100 m.
Effects of the NPY on PCT Nat K-ATPase activity
NPY (l0— to i0 M) caused a dose- (Fig. 3A) and time- (Fig.
3B) dependent stimulation of PCT Nat K-ATPase activity
when Na in the medium (Narn) was 20 m, a non-saturating
Na concentration. Half-maximal activation occurred with
NPY i0 M (2920.3 89.2 pmol Pi mmltubule/hr, 166.3% of
control values), and maximal activation occurred with i0 M
(3661.3 293.4, 200.8%). NPY had no effect on ouabain-
insensitive ATPase; it was 2633.0 186.1 and 2630.0 260.2
Fig. 3. Na, K-ATPase activity measured in single PCT segments
preincubated at Narn = 20 mM with pNPY (full peptide) in varying
concentrations at room temperature (A) and preincubation periods (B).
Nat K-ATPase activity was measured as picomoles of inorganic
phosphate per millimeter of tubule per hour. Each point is mean SEM(N = 3 to 4). *p < 0.05, < 0.01 compared with control values
(1785.7 56.0 pmol Pi mmltubule/hr) in A. In the experiments shown in
B, PCT segments were incubated at either room temperature () or
37°C (0).
for control tubules and NPY-treated (10—v M) tubules, respec-
tively.
In the experiments with preincubation with NPY or vehicle at
37°C, the stimulatory effect of NPY was more prompt, whereas
no effect was observed in the vehicle-treated study (Fig. 3B).
In Figure 4, the Na dependence of the PCT Nat K-
ATPase activity in the absence and presence of NPY is shown.
In the absence of NPY, sodium caused a half-maximal increase
in the enzyme activity at about 12 m of Na. NPY stimulated
Na, K-ATPase activity at a non-saturating Na concentra-
tion as mentioned above, but not under Vmax conditions, with a
resultant shift from 12 to 6 m of Na required for a half-
maximal increase in activity.
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Table 1. Attenuation by a-adrenergic receptor antagonists on the
stimulatory effect of NPY and its agonists on Na, K-ATPase
activity
Na, K-ATPase activity
0 10 20 30 40 50 60 70
Absolute values % of control
pNPY
pNPY + prazosin (praz)
pNPY + yohimbine (yoh)
pNPY + praz ÷ yoh
2638.7 255.8
1899.7 389.1
2076.3 491.4
1641.0 87.6
165.5
115.9
125.5
116.5
Y2 agonist
Y2 agonist + praz + yoh
2376.3 60.2
1633.0 148.6
141.5
117.3
Y1 agonist + Y2 agonist
Y1 ago + Y2 ago + praz + yoh
2254.7 76.6
1589.7 116.9
146.1
112.9
PCT segments were preincubated with NPY or its agonist (10 M)
with or without a-adrenergic receptor antagonists (10_6 M); prazosin as
a1-adrenergic antagonist and yohimbine as a2-adrenergic antagonist.
Results are given both as absolute values (pmol Pi mm/tubule/hr) and %
of control value obtained at each experiment. Each value is mean
SEM (N = 3).
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FIg. 4. Effect of NPY on Na, K-ATPase activity of single PCT
segments, as a function of Na concentration. Segments were incu-
bated 30 minutes in the absence () or presence (•) of pNPY (l0— Sf).
Na, K-ATPase activity was measured as picomoles of inorganic
phosphate per millimeter of tubule per hour (mean SEM, N = 3).NPY
decreased the Km for Na from 12 m to 6 mM.
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Fig. 5. Effect of NPY and its agonists on Na, K-ATPase activity of
single PCT segments. NPY Y2 receptor agonist, NPYI36, mimicked
the stimulatory effect of NPY. NPY Y1 receptor agonist, [Leu31, Pro34J
NPY, had less effect on the enzyme activity even at l0 M when
compared with the control values (1600.0 124.5 pmol Pi mm/tubule!
hr; P = 0.58). Error bars represent SEM (N 3 in each group).
Effects of the NPY analogs and a-adrenergic antagonists
The results from the studies with NPY and its receptor
agomsts are shown in Figure 5. The effect of NPY was
mimicked by the NPY Y2 receptor agonist, NPY1336, but not
by the NPY Y1 receptor agonist, [Leu31, Pro34] NPY. At a
concentration of iO— M, the effects of pNPY (full peptide),
NPY13 and [Leu31, Pro34] NPY on PCT Nat K-ATPase
activity were 2638.7 255.8, 2376.3 60.2, and 1670.3 16.7
pmol Pi mm/tubule/hr, respectively. [Leu31, Pro] NPY caused
no statistical increase in the enzyme activity even at l0 M.
Prazosin, a selective a1-adrenergic antagonist, and yohim-
bine, a selective a2-adrenergic antagonist, at 10—6 M attenuated
the effects of pNPY and NPY1336 (Table 1). Neither antagonist
affected the enzyme activity when added alone (data not
shown).
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Fig. 6. Synergistic effect of pNP Y and a-adrenergic agonist, oxymeta-
zoline on Nat, K-ATPase activity of single PCT segments. Subthresh-
old doses of either pNPY (5 x iO M) or oxymetazoline (lOs M) had
less stimulatory effect on Nat K4-ATPase activity; when tubules were
incubated with both drugs at those doses, the enzyme activity increased
to about 1.5-fold of control values (1692.0 126.4 pmol P1 mm/tubule/
hr). Bars represent SEM (N = 3 in each group).
Synergistic effects of NPY and a-adrenergic agonist,
oxymetazoline
As shown in Figure 6, NPY and the a-adrenergic agonist,
oxymetazoline, both at subthreshold doses, acted synergisti-
cally to stimulate PCT Na, K-ATPase activity. In tubules
incubated with NPY 5 x l0 M, the enzyme activity was
1858.0 145.4, as in tubules incubated with oxymetazoline
10—8 M, it was 1805.0 110.7; when incubated with NPY and
oxymetazoline at these doses, Nat K-ATPase activity was
2578.7 428.0, P < 0.01.
Effects of FK 506 on NPY-stimulated PCT Nat K-ATPase
activity
The stimulatory effects of pNPY and NPY1336 were com-
pletely abolished by FK 506 108 M, at a dose at which FK 506
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Na, K-ATPase activity
Absolute values % of control
pNPY
pNPY + FK 506
2638.7 255.8
1879.3 211.2
165.5
100.7
Y2 agonist
Y2 agonist + FK 506
2376.3 60.2
1512.7 53.4
141,5
102.5
Y1 agonist + Y2 agonist
Y1 ago + Y2 ago + FK 506
2254.7 108.3
1561.3 97.7
146.1
104.1
PCT segments were preincubated with NPY or its agonist(i0M)
with or without FK 506 (10_s M). FK 506 completely abolished the
effect of NPY. Results are given both as absolute values (pmol Pi
mm/tubule/hr) and % of control value obtained at each experiment.
Each value is mean SEM (N = 3).
alone had no effect on enzyme activity (Table 2). This suggests
that the action of NPY is mediated via activation of calcineurin.
Effects of pertussis toxin on NPY-stimulated PCT Na, K-
ATPase activity
In tubules preincubated with PTX, NPY-stimulated Nat,
KtATPase activity was completely blocked as shown in Table
3 (with NPY 95.5% of control value, without NPY 95.2%).
Effects of NPY on PCT Na, K-ATPase activity of the
denervated kidney
In control tubules from the denervated kidney, Na, K-
ATPase activity was 34% lower than in the control tubules from
the innervated kidney, 1184.3 200.6 pmol Pi mm/tubule/hr.
NPY stimulated Na, K-ATPase activity to the same extent in
both groups (2921.3 278.9, 163.5% of control values in
innervated groups; 1980.3 280.0, 162.0% in denervated
groups). There were no statistical differences between the NPY
effect on the Nat, K-ATPase activity of the innervated and
denervated kidneys (163.5 3.6% of control value in the
innervated kidneys, 162.0 3.9% of those in the denervated
kidneys), suggesting that exogenous NPY does not act with
endogenous NE.
Discussion
Na, K-ATPase generates energy for transcellular transport
of Na and substrates that are co- or counter-transported with
Nat In kidney tubules, it holds a key position by controlling
the reabsorptive capacity, and is reported to be stimulated by
adrenergic agents [20, 21] and angiotensin II [22, 23] and
inhibited by dopamine [24], prostaglandin E2 [25, 26], parathy-
roid hormone [27] and endothelin [28]. Here we show that NPY
increases Na, K-ATPase activity in permeabilized cells of
the PCT of rat kidney.
NPY, isolated in 1982 from porcine brain [1, 2], is one of
many neuropeptides found in the mammalian brain. In the
peripheral nervous system, NPY functions mainly as a modu-
lator/transmitter in sympathetic nerves, where it has been
shown to act together with NE in the regulation of vascular tone
[29—31]. In sympathetic nerves NPY is generally co-localized
and released together with NE, with which it interacts both on
a presynaptic and postsynaptic level [32, 33]. Here we could
Na, K-ATPase activity
Absolute values % of control
PTX(—), NPY(+) 2101.3 107.9 150.3
PTX(+), NPY(+) 1270.7 19.2 95.5
PTX(+), NPY(—) 1266.0 41.5 95.2
PTX(—), NPY(—) 1374.0 49.5 99.5
demonstrate the colocalization of NPY with DBH, the NE-
synthetizing enzyme, in the vicinity of the rat PCT. However,
the vast majority of NPY-containing noradrenergic nerves were
observed around blood vessels. It is, however, possible that
NPY (and NE) released from perivascular nerves may diffuse
over and reach proximal tubules.
There are at least two subtypes of NPY specific receptors,
designed Y1 receptor (having a low affinity for C-terminal
fragments of NPY) and Y2 receptor (having a high affinity for
C-terminal fragments of NPY) [34, 35]. Presynaptic NPY re-
ceptors have been suggested to be of the Y2-type [34], whereas
postsynaptic receptors may include both the Y1 and Y2 types
[36]. [Leu31, Pro34] NPY, an analog of NPY modified at
residues 31 and 34, was recently found to be a specific high-
affinity ligand for Y1 receptors [37] and it is used as a selective
agonist for Y1 receptors. On the other hand, NPY1336, the NPY
peptide C-terminal fragment which binds with high affinity to Y2
receptors but rather poorly to Y1 receptors, is considered a
good ligand for the Y2 receptors [341. The stimulatory effect of
NPY on rat PCT was mimicked by NPY1336; thus, the effect
was likely to be mediated via Y2 receptors. This is consistent
with the observation that high amounts of Y2 receptors are
present in the basolateral membrane of proximal tubule cells,
especially on the basolateral membrane of pars convoluta [38].
The results shown in Table 3 indicate that the proximal
tubular NPY receptor is coupled to a PTX sensitive G-protein.
NPY Y1 receptors have recently been cloned and found to be
PTX-sensitive G-protein coupled receptors [39—41], but less is
known about the G-protein coupling of the Y2 receptors. PTX
sensitive G-protein is, like the NPY Y2 receptors and Na ,K-
ATPase, present in high concentrations [42] in basolateral
membrane of PCT cells. Furthermore, Y2 receptors on the
rabbit proximal tubule cells were found to be linked to PTX
sensitive G-protein, in the form of GTPYS [38, 43].
The result that FK 506, an immunosuppresant known to
inhibit calcineurin, PP2B [44], blocked the stimulatory effect of
NPY on PCT Na, K-ATPase activity indicates that the NPY
Y2 receptor, like the a-adrenergic receptors [10] mediates this
effect via calcineurin (Fig. 7). In unpublished studies we have
found that NPY, like a-adrenergic agonists, causes an increase
in the intracellular calcium in proximal tubule cells in primary
culture (Sahlgren B, et al, manuscript in preparation).
An interaction and synergism between NPY and NE is well
established in neuronal and vascular tissues. In the central
nervous system, the effects of NPY were attenuated by a2-
adrenergic antagonists [9]. In the periphery, NPY at lower
Table 2. Effect of FK 506, a PP2B inhibitor, on NPY-stimulated
Nat K-ATPase activity
Table 3. Effect of PTX on NPY-stimulated Nat K-ATPase activity
After PCT segments were preincubated with or without PTX at 37°C
for 4 hours, they were incubated with pNPY or vehicle for 30 minutes
at room temperature. At each experiment, control tubules were only
preincubated in microdissection solution for 30 minutes at room tem-
perature. Each value is mean SEM (N = 3).
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doses potentiates a1-receptor-mediated vasopressor responses,
whereas at higher doses, NPY per se induces vasoconstriction
which is not antagonized by adrenoceptor antagonists [45]. This
is considered to be reciprocal and threshold synergism [46] is
proposed to account for the NPYINE cooperation [8]. In the
present study, both prazosin, a selective a1-adrenergic antago-
nist, and yohimbine, a selective a2-adrenergic antagonist, at
10—6 M, partially blocked the stimulatory effects of NPY and its
analogs. On the other hand, NPY and an a-adrenergic agonist,
oxymetazoline, both at subthreshold doses, acted synergisti-
cally to stimulate PCT Nat, K-ATPase activity. To exclude
the interaction between exogenous NPY and endogenous NE
located in the kidney, some experiments were carried out on the
PCT of the denervated kidneys. Previous studies from our
department [47] showed that the DBH as well as NPY-positive
fibers almost completely disappeared after denervation. The
results obtained from the denervated kidney mimicked those
from the innervated kidney, suggesting that the effect of NPY
on Na, K-ATPase is independent of the presence of endog-
enous NE. The mechanism underlying the interaction between
NPY and NE in the kidney is presently under investigation.
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Fig. 7. A model for the signaling pathway
that NPY uses to stimulate Na, K-ATPase
activity in tubule cells. Neuropeptide Y,
released from the renal sympathetic nerve
endings, acts on NPY Y2 receptors coupled to
a PTX-sensitive G-protein (possibly of the G,
or G0 type) in the basolateral membrane of
renal PCT cells. This causes an increase in
intracellular calcium (together with
norepinephrine acting on a-adrenoceptors
[48]), an activation of PP2B, and the
activation of Na, K-ATPase, either via a
direct effect on phosphorylating Na, K-
ATPase, or via an indirect effect on an
intermediating phosphorylation cascade.
Evidence for this model are the following
observations: NPY stimulation of Na, K-
ATPase is mimicked by Y2 receptor agonists,
and attenuated in the presence of a PTX-
sensitive 0-protein and by the specific PP2B
inhibitor, FK 506. In unpublished studies, we
have found that NPY increases intracellular
Ca2 levels in proximal tubule cells in primary
culture (Sahigren B, et al, manuscript in
preparation).
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